ASCO 2022: There is still more to do

June 03, 2022
About the Author

David has over thirty years of industry experience, where he held various global executive leadership positions in large pharmaceutical and commercial-stage biotechnology companies focused on oncology.


am excited that we are once again coming together at the 2022 ASCO Annual Meeting; for some of us, for the first time in person in a long time. This meeting always reminds me not only of the significant progress being made across the many facets of oncology research, but also the scientific innovation driven by Mirati in targeting the genetic drivers of certain cancers. Even with research advancements, there is much work left to do.

Mirati is striving to bring cutting edge science to the forefront. At this year’s meeting, among other research, we are proud to present our first clinical data set on central nervous system (or CNS) activity in patients with NSCLC harboring a KRASG12C mutation. This is important because CNS metastases can occur in up to 42% of patients with non-small cell lung cancer harboring the KRASG12C mutation, and often contribute or lead to death, posing a serious clinical challenge. I’m energized by what our team is doing to address this significant unmet medical need.

Most importantly, we want to thank the patients and physicians who make the research possible. I’m grateful to the dedicated Mirati Team who remain relentless in their pursuit of helping people living with cancer, who are counting on us to make a difference in their lives.

Follow Mirati’s LinkedIn company page for updates and perspective on our science during the 2022 ASCO Annual Meeting.